医药导报2024，Vol.43Issue(9)：1440-1444,5.DOI:10.3870/j.issn.1004-0781.2024.09.014
奈玛特韦/利托那韦在慢性肾脏病合并新型冠状病毒感染患者中的应用
Application of Nirmatrelvir/Ritonavir in Patients with Chronic Kidney Disease and SARS-CoV-2 Infection
摘要
Abstract
Severe acute respiratory syndrome coronavirus-2(SARS-CoV-2)infection is a new respiratory infectious disease.Patients with chronic kidney disease are at high risk of SARS-CoV-2 infection.Once they develop SARS-CoV-2 infection,the rate of progression to severe illness or even death is much higher than that of the general population.Nirmatrelvir/ritonavir significantly reduce the risk of severe illness and death in patients infected with SARS-CoV-2.In this paper,the dosing regimen and drug interaction of nirmatrelvir/ritonavir in patients with different stages of chronic kidney disease complicated with SARS-CoV-2 infection were reviewed to provide a reference for clinical rational medication for patients with chronic kidney disease.关键词
奈玛特韦/利托那韦/新型冠状病毒感染/慢性肾脏病/透析/药物相互作用Key words
Nirmatrelvir/ritonavir/Severe acute respiratory syndrome coronavirus-2 infection/Chronic kidney disease/Dialysis/Drug interactions分类
药学引用本文复制引用
梁宝贤,逄晓云,谢可炜,车妙琳,王琴..奈玛特韦/利托那韦在慢性肾脏病合并新型冠状病毒感染患者中的应用[J].医药导报,2024,43(9):1440-1444,5.基金项目
国家自然科学基金资助项目(82000634) （82000634）
上海市青年科技英才扬帆计划(20YF1425000) （20YF1425000）
中国毒理学会临床毒理专项(CST2019CT308). （CST2019CT308）
